Skip to content

A Roll-over Observational Study for the Extended Follow-up of the Volunteers of the ISS T-003 Trial

A Roll-over Observational Study for the Extended Follow-up of the Volunteers of the ISS T-003 Trial (ISS T-003 EF-UP)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02712489
Acronym
ISST-003EF-UP
Enrollment
179
Registered
2016-03-18
Start date
2015-01-31
Completion date
2016-10-31
Last updated
2016-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

HAART-treated participants, Tat, Therapeutic immunization

Brief summary

A roll-over observational study (ISS T-003 EF-UP) is being conducted to extend the follow-up of the volunteers of the ISS T-003 trial in order to evaluate the persistence of vaccine immunogenicity as well as of the immunological and virological effects induced by the therapeutic immunization with Tat.

Detailed description

An open label, non-interventional study roll-over study (ISS T-003 EF-UP) is being conducted to follow-up the persistence of vaccine humoral responses as well as of the immunological and virological effects induced by the therapeutic immunization with Tat.To this aim volunteers of the ISS T-003 study are included in one year study, with visits at weeks 0 and 24 and 54. To assess the anti-Tat humoral immune response by the determination and titration of IgM, IgG and IgA anti-Tat antibodies (primary endpoint) and to evaluate CD4+ T cell counts and HIV-1 plasma viraemia (as secondary endpoint). In addition, depending on the availability of residual specimens (PBMC, serum and plasma), further laboratory tests (i.e. HIV DNA copies in blood) to investigate in-depth the immunological and virological profile of the volunteers is being performed. Physical examination is being performed to monitor the clinical status of the volunteers and to record the appearance of clinical signs and symptoms of disease progression as well as AIDS-defining events, data or records related to ARV treatment compliance. Pregnancy onset for female participants will also be recorded.

Interventions

OTHERNo intervention

Sponsors

Italian Ministry of Foreign Affairs - General Direction for Cooperation and Development
CollaboratorUNKNOWN
Barbara Ensoli, MD, PhD
Lead SponsorOTHER

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* previous participation in the ISS T-003 trial without withdrawal of consent; * availability to participate in the extended follow-up study; * signed informed consent.

Exclusion criteria

* The absence of any of the above criteria will exclude the participants from the study

Design outcomes

Primary

MeasureTime frameDescription
Presence of specific anti-Tat humoral immune responseThrough study completion, an average of 1 yearanti-Tat IgM, IgG, IgA antibodies

Secondary

MeasureTime frame
CD4+ T cell countsThrough study completion, an average of 1 year
HIV-1 RNA Viral LoadThrough study completion, an average of 1 year

Countries

South Africa

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 12, 2026